New French Pharma Industry Head Faces Tough Challenges On Drug Spending
Executive Summary
Leem’s new president says one of his priorities is to discuss the implementation of measures agreed earlier this year to speed up access to innovative medicines. But he also faces a number of other challenges, including the squeeze on pharmaceutical spending.
You may also be interested in...
French Industry Welcomes Moves To Speed Up Access To Innovative Drugs
A French government/industry discussion forum has come up with concrete plans for accelerating access to innovative medicines by streamlining clinical trial approval and price negotiations.
French Govt Must Act To Stop ‘Inexorable Decline’ Of Pharmaceutical Industry
The president of France’s industry association Leem says the authorities need to look at new ways of handling the health technology evaluation and pricing of innovative drugs, and to implement more predictable, long-term health policies, if the country is to reverse the “inexorable decline” of the pharmaceutical sector.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.